BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.830
EU - Europa 3.266
AS - Asia 766
AF - Africa 17
SA - Sud America 16
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 7
Totale 10.912
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.790
GB - Regno Unito 1.583
IT - Italia 489
CN - Cina 314
SE - Svezia 295
DE - Germania 282
HK - Hong Kong 221
FR - Francia 196
UA - Ucraina 159
TR - Turchia 131
FI - Finlandia 89
BG - Bulgaria 68
IN - India 29
CA - Canada 27
BE - Belgio 25
VN - Vietnam 22
IE - Irlanda 18
RU - Federazione Russa 18
IR - Iran 11
BR - Brasile 10
JP - Giappone 10
AU - Australia 9
MY - Malesia 9
CZ - Repubblica Ceca 8
EU - Europa 6
GR - Grecia 5
NL - Olanda 5
BZ - Belize 4
CH - Svizzera 4
KE - Kenya 4
MX - Messico 4
PH - Filippine 4
RO - Romania 4
SG - Singapore 4
AT - Austria 3
CL - Cile 3
EG - Egitto 3
GP - Guadalupe 3
IL - Israele 3
NG - Nigeria 3
PL - Polonia 3
RS - Serbia 3
ZA - Sudafrica 3
EC - Ecuador 2
ES - Italia 2
ET - Etiopia 2
NO - Norvegia 2
PT - Portogallo 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
CR - Costa Rica 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
MA - Marocco 1
MU - Mauritius 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
TW - Taiwan 1
Totale 10.912
Salva come PNG Salva come JPEG
Città #
Southend 1.448
Fairfield 1.059
Woodbridge 702
Ashburn 592
Chandler 497
Houston 489
Seattle 435
Wilmington 385
Cambridge 380
Ann Arbor 327
Jacksonville 313
Dearborn 261
Nyköping 246
Hong Kong 219
Modena 174
Beijing 152
San Diego 105
New York 92
Princeton 76
Sofia 68
Izmir 63
Eugene 61
Frankfurt am Main 59
Helsinki 43
Bremen 35
London 35
Redwood City 33
Fremont 31
Falls Church 27
Brussels 24
Boardman 23
Milan 23
Bologna 22
Dong Ket 20
Nanjing 17
Norwalk 17
Des Moines 16
Dublin 15
Rome 15
Shanghai 14
San Giuliano Milanese 13
San Jose 12
Phoenix 11
Rho 11
Kunming 10
San Mateo 10
Toronto 10
Hefei 9
Trabzon 9
Chengdu 8
Indiana 8
Latina 8
Chicago 7
Guangzhou 7
Hounslow 7
Kilburn 7
Ottawa 7
Parma 7
Segrate 7
São Paulo 6
Bitonto 5
Chiswick 5
Dongguan 5
Genoa 5
Hebei 5
Jinan 5
Prescot 5
Verona 5
Albuquerque 4
Athens 4
Belize City 4
Cantù 4
Dallas 4
Kuala Lumpur 4
Leawood 4
Melbourne 4
Mirandola 4
Nairobi 4
Nanchang 4
Paris 4
Philadelphia 4
Roncoferraro 4
Saint Petersburg 4
Stoneham 4
Trento 4
Washington 4
Zhengzhou 4
Abano Terme 3
Amritsar 3
Amsterdam 3
Antalya 3
Ardabil 3
Atlanta 3
Augusta 3
Berlin 3
Buffalo 3
Changsha 3
Edinburgh 3
Florence 3
Gainesville 3
Totale 8.942
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 512
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 297
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 271
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 254
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 246
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 238
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 236
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 229
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 228
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 226
Activity of BKM120 and BEZ235 against lymphoma cells 221
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 220
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 220
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. 209
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 203
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 203
Empathic attitudes among nursing students: a preliminary study 202
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 201
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 198
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 194
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 192
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 192
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 192
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 187
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 180
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 178
A concise review of lenalidomide therapy for follicular lymphoma 176
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 173
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 173
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 172
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 170
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 170
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 168
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 166
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 157
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 156
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 155
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 154
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 149
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 147
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 145
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 143
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 143
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 142
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 139
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 139
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 136
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 133
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 133
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 128
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 125
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 121
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 117
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 115
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 111
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 101
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 100
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 97
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 90
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 89
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 87
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 83
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 69
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 46
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 33
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 28
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 28
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 23
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 11
Management of multiple myeloma|Terapia del mieloma multiplo 8
Totale 11.078
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019701 0 0 0 0 0 0 0 0 0 118 296 287
2019/20202.549 220 99 72 177 265 374 379 266 279 129 151 138
2020/20212.396 279 111 184 264 341 140 138 233 118 251 224 113
2021/20221.487 62 110 181 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/2024927 58 38 75 106 232 72 199 101 33 13 0 0
Totale 11.078